: Gilead ends late-stage trial of blood cancer treatment

<p>Shares of Gilead Sciences Inc. GILD dropped nearly 2% in the extended session Friday after the pharma company said it has ended a late-stage trial of a treatment for a rare type of blood cancer after an analysis. “The health and well-being of patients are our top priorities and while this is disappointing news it […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/market-news/gilead-ends-late-stage-trial-of-blood-cancer-treatment/">: Gilead ends late-stage trial of blood cancer treatment</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>